• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Long-term follow-up of HCV patients with sustained virological response after treatment with pegylated interferon plus ribavirin

    2021-05-19 14:03:42YuanJiMaLingYaoDuLiBoYanJuanLiaoXingChengWuWeiXieHongTang

    Yuan-Ji Ma,Ling-Yao Du,Li-Bo Yan,Juan Liao,Xing Cheng,Wu-Wei Xie,Hong Tang

    Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu 610041, China

    Keywords:Hepatitis C virus Sustained virological response Hepatocellular carcinoma

    ABSTRACT Background: The progress of liver diseases may not stop after viral eradication.This study aimed to provide data on long-term prognosis of patients with hepatitis C virus (HCV) infection who underwent pegylated interferon plus ribavirin (PR) regimen and achieved a sustained virological response 24 weeks post-treatment (SVR24).Methods: Responders to the PR regimen in our hospital from January 2011 to June 2014 were enrolled and prospectively followed up.Baseline characteristics were profiled.The incidence of hepatocellular carcinoma (HCC),progression of liver disease (increase in liver stiffness or occurrence of decompensated complication),and HCV recurrence was all monitored.The accumulative and annualized incidence rates(AIRs) of these adverse events were analyzed,and the risk factors were also examined.Results: In total,151 patients reached a median follow-up time of 103 weeks.Among them,two had an incidence of HCC during the surveillance with AIR of 0.68% (95% CI:0.00-1.63%).Six patients showed progression of liver disease with AIR of 2.05% (95% CI:0.42%-3.68%).Three patients who had risky behaviors encountered HCV reinfection.The cirrhotic patients faced higher risk of poor prognosis than non-cirrhotic patients,including HCC and progression of liver disease (AIR:6.17% vs.1.42%,P=0.039).Conclusions: The incidence of HCC and progression of liver disease was evident in PR responders during the long-term follow-up period,but the risk level was low.Cirrhotic responders were more vulnerable to develop HCC post SVR24 compared with non-cirrhotic ones.HCV recurrence was rare in responders with SVR24 who had corrected their risky behaviors.

    Introduction

    Pegylated interferon (Peg-IFN) plus ribavirin (PR) regimen used to be the standard therapeutic option for patients with chronic hepatitis C (CHC) in China since the beginning of this century [1].A previous study reported that the therapeutic efficacy of the PR regimen in patients with IL-28 CC genotype reached 80% or more [2].Most patients could achieve a sustained virological response (SVR) if a full therapeutic course was completed [3].

    However,the progression of liver disease may not stop after viral eradication,especially in patients with advanced cirrhosis.A previous study also revealed that even in non-cirrhotic patients,risks still existed after an SVR was achieved [4].Therefore,patients with viral eradication are recommended to receive longterm hepatocellular carcinoma (HCC) surveillance.However,the data of long-term follow-up in treated Chinese patients are still lacking.Further investigations are needed in both cirrhotic and non-cirrhotic patients.

    In this study,we reported the long-term prognosis of hepatitis C virus (HCV)-infected patients who received a full course of PR treatment and achieved SVR 24 weeks post-treatment (SVR24).

    Methods

    Study subjects

    All subjects who were diagnosed with CHC through a positive serum HCV RNA test and had received PR regimens from January 2011 to June 2014,were recorded and prospectively followed up.The subjects who completed a full therapeutic course and achieved an SVR24 were screened.Of the PR regimens,Peg-IFNα?2a or Peg-IFNα?2b was prescribed according to physical condition and health insurance of patients and availability of drugs.Sanger sequencing with PCR kit (Daan gene,Guangzhou,China)was applied and performed on ABI9700 (Life technologies,Carlsbad,USA) to identify HCV genotype.The SVR24 was defined if the high-precision HCV RNA test was negative through“The COBASR○AmpliPrep/COBASR○ TaqManR○ HCV Test”(Roche Diagnostics,GmbH,Mannheim,Germany) 24 weeks after treatment.Then,a long-term follow-up was conducted every year to learn their prognosis.Written informed consent (Version:2016.03) was acquired from all the patients.This study was approved by the Ethics Committee of West China Hospital [Authorization Number:2016 annual audit (91)].

    Fig.1.The study flow diagram to identify the cohort of long-term follow-up.SVR24:sustained virological response 24 weeks post treatment.

    Study endpoints

    The primary endpoint of this study was the long-term prognosis,including the incidence of HCC,the progression of liver disease(increase in liver stiffness or occurrence of decompensated complication),and HCV recurrence.The secondary endpoint was the difference in long-term prognosis between cirrhotic and non-cirrhotic patients.

    HCC was identified by yearly follow-up and tracing the source medical record.The first recorded date of HCC after SVR was considered the incident date.The liver stiffness was evaluated through either transient elastography using FibroScanR○or aspartate aminotransferase (AST)-to-platelet ratio index (APRI) score every year.The increase of FibroScanR○value from<12.4 kPa to>12.4 kPa or APRI from<2.0 to>2.0 was defined as an“increase in liver stiffness”[5].The increase in liver stiffness or the occurrence of cirrhosis-related complications other than HCC was defined as progression of liver disease.

    The follow-up ended when HCC was diagnosed,the patient died,or HCV RNA was positive.Data were collected until June 1,2017.

    Statistical analysis

    Baseline characteristics were analyzed in all cohorts to give a profile of CHC patients.The incidence of HCC,progression of liver disease,and HCV recurrence were compared between cirrhotic and non-cirrhotic patients.

    All data were analyzed using SPSS 18.0 (IBM SPSS Statistics,Chicago,IL,USA).The enumeration data were expressed as percentages and analyzed with the Chi-square test or Fisher’s exact test.The measurement data were analyzed for normality first.Normally-distributed data were expressed as mean ± standard deviation (SD) and analyzed with the Student’st-test,while nonnormally-distributed data were expressed as median (interquartile range,IQR) and analyzed with theUtest.A comparison between normally-distributed data and non-normally-distributed data was also conducted via theUtest.The relationship between different indicators was analyzed with correlation or regression analysis.APvalue<0.05 was considered statistically significant.

    Results

    Baseline characteristics of the patients

    Among 220 subjects,41 encountered relapse before achieving SVR24,28 lost to follow up,151 finished long-term follow up (Fig.1).The baseline characteristics of the 151 subjects were shown in Table 1 .Half of them were males.The average age at the initial treatment was 46.0 ± 13.3 years.They were infected by various genotypes of HCV.Among them,genotype 1b HCV was the majority (76.2%),and the viral genotype could not be identified in two patients.The median baseline viral load was 6.02 (IQR 4.86–6.66) logIU/mL,while the baseline alanine aminotransferase (ALT)was 54 (IQR 31–109) IU/L.Although alpha-fetoprotein (AFP) level was elevated in 21.9% of the patients,HCC was excluded through abdominal ultrasound.

    All patients were divided into two groups according to their liver stiffness,which was measured by FibroScanR○,or elevated APRI (APRI>2.0).Among them,38 patients (25.2%) were identified as cirrhotics (Table 1).The sex distribution in the two groups showed no significant difference (55.3% vs.50.4%,P=0.607).The cirrhotic patients were significantly older (51.4 ± 8.2 vs.44.1 ± 14.2 years,P<0.001).The proportion of genotype 1b in cirrhotic patients was significantly higher than that in non-cirrhotic patients (92.1% vs.70.8%,P=0.030).ALT,antinuclear antibody,AFP,platelet and neutrophil levels were also significantly different between the two groups (Table 1).

    Table 1 Baseline characteristics of the study cohort.

    Table 2 The annualized incidence rate (AIR) of adverse events in patients under long-term surveillance after SVR24.

    Table 3 Possible risk factors related to HCV reinfection.

    Long-term follow-up

    Of the recorded 151 patients,38 were cirrhotic responders and 113 were non-cirrhotic ones.The median follow-up time was 103(IQR 77–126) weeks.Two patients had incident HCC during the long-term surveillance.The annualized incidence rate (AIR) of HCC in our cohort was 0.68% (95% CI:0.00 ?1.63%) (Table 2).Six patients showed progression of liver disease with AIR of 2.05% (95%CI:0.42% ?3.68%).Three patients encountered HCV reinfection with AIR of 1.02% (95% CI:0.00–2.18%).

    The AIRs of HCC and progression of liver disease were 0.66%and 1.32% in the patients under the first follow-up year after SVR24,respectively.In the patients under the second follow-up year after SVR24,the AIRs of HCC and progression of liver disease were both 0.93%.In addition,no incidence of HCC was observed in patients followed up for more than 3 years.It may imply that after SVR24 was achieved,the patients would be at a relatively low risk of HCC (Table 2).

    According to a previous study,HCV relapse was rare after successful SVR achievement [6].In our cohort,we observed no relapse but 3 cases of HCV reinfection in the long-term follow-up.We retrospectively reviewed the baseline characteristics and therapeutic course in these three patients and found that all had the risk factors of reinfection,among which one had hemophilia and multiple blood transfusions,one had drug injection,and one had risky sexual behavior (Table 3).

    Table 4 The annualized incidence rate (AIR) of liver deterioration in cirrhotic patients and non-cirrhotic patients.

    As no HCV relapse was found,only the incidence of HCC and progression of liver disease were calculated respectively in cirrhotic and non-cirrhotic patients (Table 4).In addition,we analyzed AIR to balance the difference of follow-up period in the two groups.The AIR of HCC was low in both groups without significant difference (1.24% vs.0.47%,P=0.447).However,the progression of liver disease was different,with marginal significance (4.94% vs.0.94%,P=0.051).Moreover,when the incidence of HCC and progression of liver disease were analyzed together,patients in the cirrhotic groups were more likely to encounter liver deterioration(HCC or progression of liver disease) even after HCV elimination(6.17% vs.1.42%,P=0.039;Table 4).These results implied that although the incidence was low after SVR,the long-term prognosis was still different between cirrhotic and non-cirrhotic patients.

    Discussion

    HCV-related liver cirrhosis occurs at a rate of 2% ?30% depending on age,sex,and transmission route if HCV infection is left untreated [7,8].In addition,once liver cirrhosis is confirmed,the morbidity of the decompensated cirrhosis is 3% ?4% yearly and that of HCC is 2% ?4% yearly [9].Both statuses are associated with high mortality.Antiviral therapy is aimed to eradicate HCV,ease liver damage,and stop disease progression.

    However,eradication of the virus sometimes did not result in a real cure of the disease,and the patients faced a risk of disease deterioration afterward.A retrospective study in Japan showed that the ten-year accumulative incident risk of HCC was up to 4.3% in patients with diabetes mellitus or elevated fibrosis-4 index after SVR was achieved through interferon-based regimens [10].Consistently,we also observed some incident HCC cases.Our accumulative AIR of HCC was relatively lower than the previous reports [9,10].However,when the incidence of progression of liver disease was simultaneously calculated,the accumulative AIR of liver deterioration (HCC or progression of liver disease) was 2.73%.Another large-scale observational study also implied that the risk of HCC remained elevated for several years after SVR12 was achieved through an interferon-based treatment [11].The annual risk of HCC incidence was about 0.3% [11].In our study,the risk of HCC incidence was 0.66% in the first year after SVR24 and 0.93% in the second year,and no more cases were found in the remaining years which may due to limited sample size.However,progression of liver disease was still found in the third and fourth years.

    Previous studies [9-11]highlighted that patients with cirrhosis,diabetes or who are elderly have a higher risk of HCC incidence.In addition,cirrhosis is an independent risk factor of HCC incidence and disease progression.It was reported that patients with HCVinduced cirrhosis have an annual risk of 1% for HCC and 2% for disease progression [12].The present study compared the longterm prognosis between cirrhotic and non-cirrhotic patients.Although the incident risk was not significantly different in the two groups,an elevated incidence of liver deterioration (HCC or progression of liver disease) was noted in HCV-induced cirrhotic patients compared with non-cirrhotic ones.Several large trials analyzed the progression of liver disease in previously HCV-infected subjects and found that 1% ?14% of them have disease progression [11,13,14].HCV alters glucose metabolism and leads to insulin resistance,sequentially resulting in accelerated fibrogenesis [15].This phenomenon may sustain post SVR.Meanwhile,the hepatic stellate cells,which were reverted to quiescence after SVR,may be reactivated [16].We observed several cases of progression of liver disease.In addition,the incidence of progression of liver disease was correlated with hepatic stellate cells activity in cirrhotic patients.As advanced fibrosis or cirrhosis increases the risk of HCC incidence after HCV eradication [17],the incidence of HCC may increase as the follow-up period is extended.

    We have reviewed the latest studies on long-term follow-up of Chinese patients,and the follow-up period of our study is longer than these studies [18–20].Most studies [18,19]reported prognosis at SVR24.In the long-term follow-up with an average period of 4.3 years in“CCgenos”program,334 patients received interferon-based treatment and 71.1% of them achieved SVR24 after treatment [18].In their observation,the risk score of cirrhosis and HCC shifted towards lower among patients who achieved SVR24.The probability for treated patients to develop cirrhosis decreased from 29% to 4%after SVR24.A trend toward reduced probability of HCC progression was also implied from the study although no significance was found.Our long-term follow-up started in patients who achieved SVR24.Extremely low incidence of cirrhosis,decompensated complications and HCC were found in our study which is also consisting with previous publications [18,19].Another study followed 265 patients who achieved SVR24 for over 1931 person-years,which reported that the incidence of HCC was higher in patients with advanced fibrosis (F3-4) [19].Our study also proved that liver cirrhosis was a critical risk factor for HCC in patients who achieved SVR24.

    Notably,a previous study reported no recurrence of HCV infection in a cohort of 197 sustained responders [5].These responders experienced a follow-up period for at least 12 months to confirm their SVR and an extra median follow-up period of 17 months.In our cohort with SVR24,we observed no HCV relapse but some cases of HCV reinfection in the long-term follow-up.According to our retrospective review,we found that these patients had potential risks of reinfection (drug injection,risky sexual behavior,or multiple blood transfusions).The recurrent viral genotype in the patient with drug injection was 3b,consistent with our previous publication [20].

    Direct-acting antiviral agents (DAAs) application has increased the rate of SVR24 to more than 90%,even close to 100% in certain patients with certain regimens.However,it is still not clear as which regimen,PR or DAAs,would provide a better long-term prognosis [21,22].Interferon has a potential anti-tumor capacity.When therapeutic type I interferon is given,interferon pathways is activated,and the type II interferon from immunocytes is secreted.Previous studies proved that type II interferon directly inhibits cell growth,promotes apoptosis,stimulates the secretion of reactive oxygen species and perforin from natural killer cells and macrophages,and promotes T lymphocyte transformation into Th1 cell and CD8+CTL [23,24].Multiple mechanisms are associated with the anti-tumor effect of interferon.Although DAAs have been approved in most countries in recent years,its long-term follow-up data are still lacking.Most studies [21,22,25]focus on the SVR12 or short-term prognosis within 2 years after treatment.Reddy KR et al.[25]conducted an observational study on clinical trial recipients of daclatasvir-based regimens after SVR12 was achieved and it turned out that the SVR was durable in 99% of recipients.Progression of liver disease and new HCC were found in 15 and 23 patients respectively,indicating that the risk existed but it was infrequent.The result is consistent with ours.It implied that no matter which kind of antivirals was applied,prognosis is improved after viral eradication.We hope comparable follow-up data over 5 years provided more clear evidence.

    In conclusion,we reported the long-term prognosis of HCVinfected individuals who experienced a SVR24 after PR treatment.HCC event and progression of liver disease did exist in our cohort,but at a low rate.Cirrhotic patients were more vulnerable during treatment or post SVR.More cirrhotic patients would experience adjusted regimens compared with non-cirrhotic patients.Cirrhotic patients had a higher risk of poor prognosis after treatment.HCV recurrence was rare in responders with SVR24 who had corrected their risky behaviors.

    Acknowledgments

    We sincerely thank Rui-Chao Yu and Sanin Andres for their help in English revision.

    CRediT authorship contribution statement

    Yuan-Ji Ma:Formal analysis,Writing– original draft,Writing– review &editing.Ling-Yao Du:Data curation,Formal analysis,Writing– review &editing.Li-Bo Yan:Data curation and Validation.Juan Liao:Investigation.Xing Cheng:Resources.Wu-WeiXie:Project administration.Hong Tang:Conceptualization,Funding acquisition,Writing– review &editing.

    Funding

    This study was supported by the Research Project of Health Commission of Sichuan Province (No.17PJ006).

    Ethical approval

    This study was approved by the Ethics Committee of West China Hospital,Chengdu,China [Authorization number:2016 annual audit (91)].

    Competing interest

    No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

    久久久久久久亚洲中文字幕| tube8黄色片| 下体分泌物呈黄色| 亚洲精品国产色婷婷电影| 五月伊人婷婷丁香| 欧美精品国产亚洲| 极品少妇高潮喷水抽搐| 免费播放大片免费观看视频在线观看| 80岁老熟妇乱子伦牲交| 热99国产精品久久久久久7| av免费在线看不卡| 日韩,欧美,国产一区二区三区| 精品卡一卡二卡四卡免费| 精品酒店卫生间| 80岁老熟妇乱子伦牲交| 免费少妇av软件| 成人综合一区亚洲| 亚洲精品一区蜜桃| 丰满迷人的少妇在线观看| 日本av免费视频播放| 精品人妻偷拍中文字幕| 婷婷色av中文字幕| 国产女主播在线喷水免费视频网站| 爱豆传媒免费全集在线观看| 伦理电影免费视频| 日韩人妻精品一区2区三区| 国产一区二区三区综合在线观看 | 亚洲少妇的诱惑av| 9热在线视频观看99| 99久久中文字幕三级久久日本| 国产午夜精品一二区理论片| 亚洲国产精品成人久久小说| 伦理电影免费视频| 精品酒店卫生间| 最近2019中文字幕mv第一页| 久久久国产一区二区| 亚洲国产av新网站| 免费高清在线观看视频在线观看| 三上悠亚av全集在线观看| 亚洲av成人精品一二三区| 亚洲人成网站在线观看播放| 久久久久网色| 在线观看免费高清a一片| 午夜av观看不卡| 夫妻性生交免费视频一级片| 久久久久久久久久成人| 蜜桃在线观看..| 国产一区有黄有色的免费视频| 18禁观看日本| 久久人人爽人人片av| 精品久久久精品久久久| 老女人水多毛片| 久久久久视频综合| 国产精品久久久久久精品古装| 91在线精品国自产拍蜜月| 精品国产一区二区久久| 看免费成人av毛片| 热re99久久精品国产66热6| 国语对白做爰xxxⅹ性视频网站| 一级片免费观看大全| www.av在线官网国产| 国产深夜福利视频在线观看| 精品国产国语对白av| 又大又黄又爽视频免费| 中文欧美无线码| 这个男人来自地球电影免费观看 | 在线看a的网站| 99久久人妻综合| 午夜免费鲁丝| 永久免费av网站大全| 伦精品一区二区三区| 男人添女人高潮全过程视频| 老熟女久久久| 亚洲国产成人一精品久久久| 99热全是精品| 中文乱码字字幕精品一区二区三区| 人人妻人人添人人爽欧美一区卜| 一本色道久久久久久精品综合| 纵有疾风起免费观看全集完整版| 亚洲三级黄色毛片| 美女内射精品一级片tv| 99久久中文字幕三级久久日本| 日韩制服骚丝袜av| 我的女老师完整版在线观看| 久久久久视频综合| av福利片在线| 少妇人妻久久综合中文| 看十八女毛片水多多多| 中文字幕亚洲精品专区| 国产成人a∨麻豆精品| 亚洲欧洲精品一区二区精品久久久 | 校园人妻丝袜中文字幕| 男女边吃奶边做爰视频| 黑人猛操日本美女一级片| 日韩中文字幕视频在线看片| 婷婷色麻豆天堂久久| 男女下面插进去视频免费观看 | 男女国产视频网站| 爱豆传媒免费全集在线观看| 在线观看免费视频网站a站| 精品亚洲乱码少妇综合久久| 高清欧美精品videossex| 亚洲av福利一区| 交换朋友夫妻互换小说| 欧美日韩综合久久久久久| 丝袜喷水一区| 少妇人妻精品综合一区二区| 精品第一国产精品| 亚洲精品色激情综合| 91aial.com中文字幕在线观看| 男女边摸边吃奶| 人成视频在线观看免费观看| 免费观看在线日韩| 中文字幕人妻丝袜制服| 大陆偷拍与自拍| av黄色大香蕉| 久久人人爽av亚洲精品天堂| 制服诱惑二区| 精品人妻在线不人妻| 黄色 视频免费看| 国产熟女午夜一区二区三区| 大话2 男鬼变身卡| 欧美xxⅹ黑人| 天堂中文最新版在线下载| 精品国产露脸久久av麻豆| 欧美日韩综合久久久久久| 色94色欧美一区二区| 伦精品一区二区三区| 秋霞伦理黄片| 欧美成人午夜免费资源| 久久久亚洲精品成人影院| 亚洲成av片中文字幕在线观看 | 亚洲av男天堂| 国产乱来视频区| xxx大片免费视频| 国产国拍精品亚洲av在线观看| 99精国产麻豆久久婷婷| 久久国产精品男人的天堂亚洲 | 成人毛片a级毛片在线播放| 国产白丝娇喘喷水9色精品| 国产在线视频一区二区| 久久婷婷青草| 久久精品熟女亚洲av麻豆精品| 国产av一区二区精品久久| 国产又色又爽无遮挡免| 日韩在线高清观看一区二区三区| 一级爰片在线观看| 日韩精品免费视频一区二区三区 | 国产色婷婷99| 韩国av在线不卡| 啦啦啦视频在线资源免费观看| 又粗又硬又长又爽又黄的视频| 菩萨蛮人人尽说江南好唐韦庄| 母亲3免费完整高清在线观看 | 亚洲国产色片| 国产高清国产精品国产三级| 国产精品免费大片| 黑人高潮一二区| 国产国拍精品亚洲av在线观看| 精品一区在线观看国产| 欧美日韩视频高清一区二区三区二| xxxhd国产人妻xxx| 午夜免费鲁丝| 婷婷色综合www| 国产精品免费大片| 这个男人来自地球电影免费观看 | 久久久国产一区二区| 亚洲欧美一区二区三区黑人 | 捣出白浆h1v1| 久久久久精品人妻al黑| 免费高清在线观看日韩| 免费观看在线日韩| 精品人妻偷拍中文字幕| 亚洲熟女精品中文字幕| 国产一区二区三区av在线| 制服诱惑二区| 看非洲黑人一级黄片| 色哟哟·www| 高清不卡的av网站| 蜜桃国产av成人99| 国产伦理片在线播放av一区| 亚洲一码二码三码区别大吗| 日本wwww免费看| 亚洲美女黄色视频免费看| 90打野战视频偷拍视频| 最近中文字幕2019免费版| 美女脱内裤让男人舔精品视频| 丝袜人妻中文字幕| 五月伊人婷婷丁香| 亚洲综合色惰| 亚洲内射少妇av| 国产视频首页在线观看| 精品国产一区二区久久| 亚洲国产精品一区二区三区在线| 国产成人精品久久久久久| 99视频精品全部免费 在线| 国产女主播在线喷水免费视频网站| 看十八女毛片水多多多| 五月开心婷婷网| 一级片免费观看大全| 免费在线观看黄色视频的| 日韩av免费高清视频| 啦啦啦中文免费视频观看日本| 高清欧美精品videossex| 狂野欧美激情性bbbbbb| 内地一区二区视频在线| 人妻 亚洲 视频| 欧美人与善性xxx| 另类精品久久| 国产一级毛片在线| 国产日韩欧美视频二区| 久久久久精品性色| 亚洲欧美日韩另类电影网站| 热99国产精品久久久久久7| 一区二区三区乱码不卡18| 99久国产av精品国产电影| av在线播放精品| 国产精品久久久久久av不卡| 校园人妻丝袜中文字幕| 久久久久久久精品精品| 美女内射精品一级片tv| 久久久久网色| 内地一区二区视频在线| 国产色婷婷99| 看十八女毛片水多多多| 亚洲一码二码三码区别大吗| 看免费成人av毛片| 欧美 日韩 精品 国产| 国产片内射在线| 中国国产av一级| 久久99热这里只频精品6学生| 亚洲高清免费不卡视频| 2021少妇久久久久久久久久久| 在现免费观看毛片| 免费黄色在线免费观看| 内地一区二区视频在线| 两个人免费观看高清视频| 久久精品人人爽人人爽视色| 中文天堂在线官网| 又大又黄又爽视频免费| 成人国语在线视频| 制服人妻中文乱码| 最近手机中文字幕大全| 欧美成人精品欧美一级黄| 乱码一卡2卡4卡精品| 日本91视频免费播放| 中国美白少妇内射xxxbb| 精品酒店卫生间| 日韩人妻精品一区2区三区| 视频区图区小说| av免费在线看不卡| 亚洲国产精品一区三区| 久久精品国产综合久久久 | 三级国产精品片| 日韩一区二区三区影片| 熟妇人妻不卡中文字幕| 少妇被粗大的猛进出69影院 | 最近最新中文字幕大全免费视频 | 中文字幕人妻丝袜制服| 街头女战士在线观看网站| 国产一区二区在线观看av| 九色成人免费人妻av| 男男h啪啪无遮挡| 亚洲av综合色区一区| 少妇精品久久久久久久| 亚洲精品美女久久av网站| 高清在线视频一区二区三区| kizo精华| 色5月婷婷丁香| 中文字幕另类日韩欧美亚洲嫩草| 99国产综合亚洲精品| 肉色欧美久久久久久久蜜桃| 亚洲av国产av综合av卡| 亚洲一区二区三区欧美精品| 国产精品国产三级专区第一集| 亚洲av日韩在线播放| 男人操女人黄网站| 国产一区二区三区av在线| 有码 亚洲区| 五月天丁香电影| 飞空精品影院首页| 99国产精品免费福利视频| 91国产中文字幕| 我的女老师完整版在线观看| 日韩成人av中文字幕在线观看| 一二三四在线观看免费中文在 | 亚洲在久久综合| 街头女战士在线观看网站| 欧美国产精品一级二级三级| 婷婷色综合www| 麻豆乱淫一区二区| 国产 精品1| 97人妻天天添夜夜摸| 亚洲精品国产av蜜桃| 久久精品国产亚洲av天美| 黑人巨大精品欧美一区二区蜜桃 | 最黄视频免费看| 男女高潮啪啪啪动态图| 老司机影院成人| 涩涩av久久男人的天堂| 国产一区二区激情短视频 | 99久久精品国产国产毛片| 国产黄色视频一区二区在线观看| 99久久人妻综合| 久久久久精品人妻al黑| 欧美精品人与动牲交sv欧美| 又大又黄又爽视频免费| 日韩av免费高清视频| av在线播放精品| 人妻系列 视频| 赤兔流量卡办理| 边亲边吃奶的免费视频| 亚洲精品乱久久久久久| 又黄又粗又硬又大视频| 最近的中文字幕免费完整| 极品少妇高潮喷水抽搐| 91精品三级在线观看| 99国产综合亚洲精品| 又大又黄又爽视频免费| 色哟哟·www| www日本在线高清视频| 在线观看www视频免费| 青春草视频在线免费观看| 久久99一区二区三区| 亚洲成国产人片在线观看| 亚洲综合精品二区| 欧美97在线视频| 边亲边吃奶的免费视频| 国产激情久久老熟女| 大香蕉97超碰在线| 亚洲第一av免费看| 午夜福利网站1000一区二区三区| 啦啦啦在线观看免费高清www| 亚洲av在线观看美女高潮| 最近的中文字幕免费完整| 天天躁夜夜躁狠狠躁躁| 亚洲国产看品久久| 美女脱内裤让男人舔精品视频| 男女啪啪激烈高潮av片| www.熟女人妻精品国产 | 少妇的逼水好多| 女性生殖器流出的白浆| 国产一区二区在线观看日韩| 菩萨蛮人人尽说江南好唐韦庄| 搡老乐熟女国产| 高清不卡的av网站| 成人无遮挡网站| 建设人人有责人人尽责人人享有的| 亚洲精品中文字幕在线视频| 成年人免费黄色播放视频| 久久精品国产自在天天线| 美女福利国产在线| 久久久久久人妻| 色网站视频免费| 777米奇影视久久| 熟女人妻精品中文字幕| 少妇的逼水好多| 男女免费视频国产| 亚洲av国产av综合av卡| 男女边吃奶边做爰视频| www日本在线高清视频| 三上悠亚av全集在线观看| 中国美白少妇内射xxxbb| 蜜臀久久99精品久久宅男| 成人影院久久| 最近的中文字幕免费完整| 久久久精品免费免费高清| 中文字幕人妻丝袜制服| 99热网站在线观看| 久久国内精品自在自线图片| 丁香六月天网| 狠狠婷婷综合久久久久久88av| 一本色道久久久久久精品综合| 一区二区三区乱码不卡18| 又黄又爽又刺激的免费视频.| 你懂的网址亚洲精品在线观看| 少妇的丰满在线观看| 欧美人与性动交α欧美软件 | 欧美亚洲 丝袜 人妻 在线| 国产男人的电影天堂91| 九色亚洲精品在线播放| 亚洲,欧美精品.| 婷婷色综合大香蕉| 国产精品久久久久久av不卡| 一个人免费看片子| 一级片免费观看大全| 美女xxoo啪啪120秒动态图| 国产欧美日韩一区二区三区在线| 老司机影院毛片| 精品午夜福利在线看| 青青草视频在线视频观看| 黄网站色视频无遮挡免费观看| 亚洲,欧美精品.| 日韩伦理黄色片| 美女福利国产在线| 亚洲欧美色中文字幕在线| 日韩人妻精品一区2区三区| 人人妻人人添人人爽欧美一区卜| 男女午夜视频在线观看 | 大香蕉97超碰在线| www.av在线官网国产| 国产极品粉嫩免费观看在线| 久久韩国三级中文字幕| 少妇精品久久久久久久| 这个男人来自地球电影免费观看 | 午夜福利,免费看| 日韩精品有码人妻一区| 国内精品宾馆在线| 国产毛片在线视频| 少妇人妻久久综合中文| 国产精品一区www在线观看| 免费看光身美女| 国产精品人妻久久久影院| 一级黄片播放器| 国产一区二区激情短视频 | av不卡在线播放| 精品亚洲乱码少妇综合久久| 成人毛片a级毛片在线播放| 亚洲成国产人片在线观看| 9热在线视频观看99| 精品国产一区二区三区四区第35| 亚洲精品aⅴ在线观看| 精品久久蜜臀av无| www日本在线高清视频| 亚洲国产精品999| 国产精品嫩草影院av在线观看| 午夜精品国产一区二区电影| 亚洲av日韩在线播放| 成人18禁高潮啪啪吃奶动态图| 天天躁夜夜躁狠狠躁躁| 国产成人精品久久久久久| 青青草视频在线视频观看| 内地一区二区视频在线| 中文字幕另类日韩欧美亚洲嫩草| 久久久久久伊人网av| av女优亚洲男人天堂| 国产精品国产av在线观看| 欧美人与性动交α欧美精品济南到 | 欧美xxxx性猛交bbbb| 亚洲精品一二三| 99热国产这里只有精品6| 亚洲精品国产av成人精品| 日韩精品免费视频一区二区三区 | 久久久国产一区二区| 99热这里只有是精品在线观看| 大香蕉久久网| 久久人人爽人人爽人人片va| 久久久精品区二区三区| 大陆偷拍与自拍| 成人影院久久| 十八禁高潮呻吟视频| 18在线观看网站| 色网站视频免费| 国产精品三级大全| 自线自在国产av| 天天操日日干夜夜撸| 国产免费视频播放在线视频| 国产一区有黄有色的免费视频| 蜜臀久久99精品久久宅男| 欧美人与性动交α欧美软件 | 久久久久国产精品人妻一区二区| 99国产精品免费福利视频| 国产精品人妻久久久影院| 另类精品久久| 香蕉丝袜av| 国产男女内射视频| 天天躁夜夜躁狠狠躁躁| 22中文网久久字幕| 精品卡一卡二卡四卡免费| 中国美白少妇内射xxxbb| 国产精品国产三级国产av玫瑰| 亚洲成人一二三区av| 日本-黄色视频高清免费观看| 美女xxoo啪啪120秒动态图| 巨乳人妻的诱惑在线观看| 99香蕉大伊视频| 少妇 在线观看| 日本-黄色视频高清免费观看| 国产av国产精品国产| 另类亚洲欧美激情| 日韩三级伦理在线观看| 一级黄片播放器| 捣出白浆h1v1| 欧美另类一区| 晚上一个人看的免费电影| 大陆偷拍与自拍| 国产精品欧美亚洲77777| 亚洲国产欧美日韩在线播放| 国产免费一级a男人的天堂| 欧美精品av麻豆av| 久久人人97超碰香蕉20202| 狠狠婷婷综合久久久久久88av| 免费av中文字幕在线| 999精品在线视频| 中文字幕另类日韩欧美亚洲嫩草| 男女高潮啪啪啪动态图| 国产色爽女视频免费观看| 欧美精品一区二区免费开放| 中文乱码字字幕精品一区二区三区| 黄色一级大片看看| 亚洲欧洲精品一区二区精品久久久 | 激情视频va一区二区三区| 亚洲一码二码三码区别大吗| 99久久综合免费| 高清视频免费观看一区二区| 多毛熟女@视频| 国产一区有黄有色的免费视频| 婷婷色综合大香蕉| 日韩 亚洲 欧美在线| av网站免费在线观看视频| 丰满少妇做爰视频| 久久av网站| 黑人猛操日本美女一级片| 久热这里只有精品99| 亚洲内射少妇av| 精品视频人人做人人爽| 日日撸夜夜添| 性色av一级| 国产永久视频网站| 国产av国产精品国产| 18+在线观看网站| √禁漫天堂资源中文www| av在线老鸭窝| 日韩制服骚丝袜av| 亚洲av综合色区一区| 国产永久视频网站| 国产亚洲精品久久久com| 日本黄色日本黄色录像| 欧美少妇被猛烈插入视频| 一级爰片在线观看| 亚洲av.av天堂| 亚洲美女搞黄在线观看| 制服诱惑二区| a级毛色黄片| 亚洲精品自拍成人| 五月天丁香电影| 久久人妻熟女aⅴ| 一级毛片我不卡| 久久久国产精品麻豆| 91在线精品国自产拍蜜月| kizo精华| 精品一区在线观看国产| 精品一区二区三卡| 99久久中文字幕三级久久日本| 久久精品国产鲁丝片午夜精品| 婷婷色麻豆天堂久久| 亚洲人与动物交配视频| 精品福利永久在线观看| 我要看黄色一级片免费的| 99国产综合亚洲精品| 99久久综合免费| 国产白丝娇喘喷水9色精品| 国产成人免费无遮挡视频| 另类亚洲欧美激情| 国产精品免费大片| 国产淫语在线视频| 亚洲av福利一区| 丝袜喷水一区| 18禁裸乳无遮挡动漫免费视频| 亚洲精品一区蜜桃| 精品一区二区免费观看| 久久久久久人妻| 成人国产麻豆网| 日韩制服丝袜自拍偷拍| 亚洲国产av新网站| 女的被弄到高潮叫床怎么办| 久久精品国产自在天天线| 欧美成人精品欧美一级黄| 国产精品一国产av| 久久久精品区二区三区| 午夜日本视频在线| 一边摸一边做爽爽视频免费| 国产永久视频网站| 九色亚洲精品在线播放| 一级片免费观看大全| 国产成人aa在线观看| 日韩av不卡免费在线播放| 一二三四在线观看免费中文在 | 亚洲熟女精品中文字幕| 欧美3d第一页| 两性夫妻黄色片 | 久久毛片免费看一区二区三区| 国国产精品蜜臀av免费| av视频免费观看在线观看| 成人影院久久| 亚洲,欧美精品.| 国产综合精华液| 捣出白浆h1v1| 少妇猛男粗大的猛烈进出视频| 亚洲中文av在线| 美女内射精品一级片tv| 色网站视频免费| 春色校园在线视频观看| 天堂中文最新版在线下载| 精品一区二区三区视频在线| 国产成人精品久久久久久| 婷婷色综合www| 插逼视频在线观看| 成年人午夜在线观看视频| 天堂中文最新版在线下载| 亚洲精品国产av成人精品| 在线看a的网站| 五月天丁香电影| 性高湖久久久久久久久免费观看| 午夜免费鲁丝| 女人久久www免费人成看片| 最近中文字幕高清免费大全6| 欧美+日韩+精品| 午夜免费鲁丝| 亚洲中文av在线| 午夜福利视频精品| 亚洲成色77777| 国产精品熟女久久久久浪| 永久网站在线| 亚洲精品日本国产第一区|